434 related articles for article (PubMed ID: 25424991)
1. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
[TBL] [Abstract][Full Text] [Related]
2. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
[TBL] [Abstract][Full Text] [Related]
5. Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial.
Reischig T; Kacer M; Hruba P; Hermanova H; Hes O; Lysak D; Kormunda S; Bouda M
BMC Infect Dis; 2018 Nov; 18(1):573. PubMed ID: 30442095
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
[TBL] [Abstract][Full Text] [Related]
7. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D
Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540
[TBL] [Abstract][Full Text] [Related]
8. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
[TBL] [Abstract][Full Text] [Related]
9. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
Reischig T; Hribova P; Jindra P; Hes O; Bouda M; Treska V; Viklicky O
J Am Soc Nephrol; 2012 Sep; 23(9):1588-97. PubMed ID: 22917575
[TBL] [Abstract][Full Text] [Related]
11. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
[TBL] [Abstract][Full Text] [Related]
12. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
[TBL] [Abstract][Full Text] [Related]
13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
14. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
15. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
Kacer M; Kielberger L; Bouda M; Reischig T
Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
17. Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: Long-term Results After 7 Years of a Randomized Clinical Trial.
Witzke O; Nitschke M; Bartels M; Wolters H; Wolf G; Reinke P; Hauser IA; Alshuth U; Kliem V
Transplantation; 2018 May; 102(5):876-882. PubMed ID: 29166336
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Valacyclovir for Cytomegalovirus Infection Prophylaxis After a Heart Transplant.
Kervan U; Kucuker SA; Kocabeyoglu SS; Unal EU; Ozatik MA; Sert DE; Kavasoglu K; Tezer AY; Pac M
Exp Clin Transplant; 2016 Oct; 14(5):551-554. PubMed ID: 26976362
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
Kielberger L; Bouda M; Jindra P; Reischig T
Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353
[TBL] [Abstract][Full Text] [Related]
20. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
